v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Alternate Names:  v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)
Alternate Symbols:  c-MAF
PharmGKB Accession Id: PA30534


Cytogenetic Location: chr16 : q23.2 - q23.2
GP mRNA Boundary: chr16 : 79627745 - 79634622
GP Gene Boundary: chr16 : 79624745 - 79644622
Strand: minus


UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Tacrolimus/Cyclosporine Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of tacrolimus and cyclosporine, as well as the candidate genes believed to interact with the two drugs.

External Pathways

Links to non-PharmGKB pathways.

  1. Calcineurin-regulated NFAT-dependent transcription in lymphocytes - (Pathway Interaction Database NCI-Nature Curated)
  2. gata3 participate in activating the th2 cytokine genes expression - (BioCarta via Pathway Interaction Database)

Publications related to MAF: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A supersized list of obesity genes. Nature genetics. 2009. Hofker Marten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nature genetics. 2009. Meyre David, et al. PubMed


MAF_HUMAN (O75444)
Comparative Toxicogenomics Database:
HumanCyc Gene:

Common Searches